Evaxion A (EVAX) Total Non-Current Liabilities (2021 - 2025)
Evaxion A posted quarterly Total Non-Current Liabilities of $7.1 million for Q4 2025, down 27.2% year-on-year from $9.8 million in Q4 2024, and down 34.76% on a QoQ basis from $10.9 million in Q2 2025.
Evaxion A (EVAX) has 5 years of Total Non-Current Liabilities data on file, last reported at $7.1 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities fell 27.2% year-over-year to $7.1 million; the trailing twelve-month figure through Dec 2025 stood at $7.1 million (down 27.2% YoY), and the FY2025 full-year result was $7.1 million, down 27.2% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $7.1 million, down from $10.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $10.9 million in Q2 2025 and bottomed at $1.0 million in Q2 2021.
- The 5-year median for Total Non-Current Liabilities is $9.8 million (2024), against an average of $7.5 million.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities surged 819.77%; it then declined 27.2% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $3.4 million in 2021, then surged by 192.68% to $10.0 million in 2022, then rose by 5.76% to $10.5 million in 2023, then dropped by 7.26% to $9.8 million in 2024, then decreased by 27.2% to $7.1 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $7.1 million (Q4 2025), $10.9 million (Q2 2025), and $9.8 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 746.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.11 Mn |
| Jun 30, 2025 | 10.90 Mn |
| Dec 31, 2024 | 9.77 Mn |
| Jun 30, 2024 | 10.16 Mn |
| Dec 31, 2023 | 10.53 Mn |
| Jun 30, 2023 | 10.17 Mn |
| Dec 31, 2022 | 9.96 Mn |
| Jun 30, 2022 | 9.45 Mn |
| Mar 31, 2022 | 10.01 Mn |
| Dec 31, 2021 | 3.40 Mn |
| Sep 30, 2021 | 3.54 Mn |
| Jun 30, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.11 Mn |